Mobile website

Name: Jiangxi Biological Products Research Institute Co., Ltd.

Address: National Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province


All rights reserved:Jiangxi Biological Products Research Institute Co., Ltd.

Jiangxi ICP05034294​  Powered by


China's biotechnology development momentum is like a rainbow

China's biotechnology development momentum is like a rainbow

Industry news
2014/10/06 15:21
Page view
  With the rapid development of science and technology, the bioengineering and new drug market is extremely active, especially in the past few years when China and the world pharmaceutical market are gradually merging. The biomedical industry is rapidly emerging. Under the stock market speculation, chemical drugs are the main manufacturing. Industry is rapidly moving closer to bioengineering technology products. Today, with the slow development of chemical innovation drugs, the characteristics of bioengineering drugs have become increasingly prominent and have attracted more and more attention.
  Gene products are springing up
  Biotechnology drugs refer to proteins, antibodies or nucleic acid drugs developed by DNA recombination technology or monoclonal antibody technology, or other new biological technologies. They are the most active, fastest-growing, and most successful fields in modern science. The drug has been widely used in the treatment of many difficult diseases, and the biotechnology drug market has mushroomed rapidly.
  Research results of recombinant protein and recombinant peptide drugs, recombinant DNA drugs, and molecular cloning, gene recombination technology, and microecological preparations have gradually entered commercialization. Among them, recombinant proteins and recombinant peptide drugs have been developed and marketed, mainly cytokines. Drugs: interleukins, interferons, tumor necrosis factor, epidermal growth factor; recombinant thrombolytic drugs: recombinant streptokinase, recombinant staphylokinase, humanized monoclonal antibody preparation; and recombinant vaccine and anti-cytokine therapeutic drugs. The recombinant DNA drugs in the research and development stage include oligonucleotide drugs, antisense nucleosides, gene drugs, and cell therapy preparation vaccines. By the beginning of 2004, there were more than 2,200 biotech drugs in the world, and the United States has approved more than 170 biotech drugs, which are causing market changes.
  According to the DCAT meeting report held by IMS Health in New York in March 2004, global biopharmaceutical sales have grown at an average annual rate of 30% in recent years. In 2003, the global biomedical market value reached 37 billion US dollars. Among the "bomb" drugs, the proportion of biotechnology drugs will increase day by day. Biotechnology products in the clinical research stage account for 1/4 of all R&D drugs, which has become a growth point to promote the profits of the global pharmaceutical market.
  Biological industry grows rapidly
  Biotechnology drugs are the key projects for the development of China. Since the 1980s, great progress has been made, and biological products, biochemical drugs, and microbial drugs have gradually developed into bioengineering technology drugs. Many biopharmaceutical companies and research institutes have made great efforts to make full use of this most efficient lead compound on the basis of natural biochemical drugs, and have achieved certain results. Its representative product, recombinant human interferon alpha 1b, has been successfully developed, marking a substantial advance in DNA recombination technology. With the cooperation of biotechnology and the pharmaceutical industry, and the continuous integration of many resources. At present, China's biopharmaceutical companies have grown to more than 200, of which about one-third are enterprises with genetic engineering drug products.
  China's genetic technology research and development started late, bio-engineering pharmaceutical industry is an emerging industry, and there is a big gap with developed countries, mainly in small scale, fewer varieties, and insufficient innovation capacity. This is an indisputable fact. However, the research and development of the product has taken a short-cut path and has the characteristics of quick start. To be exact, since the listing of the first bio-engineering drug β-interferon in China in 1989, China’s reorganized interference has occurred in 2003. 21 kinds of genetic engineering drugs such as erythropoietin, interleukin-2, human growth hormone, staphylokinase, recombinant human tumor necrosis factor, nerve growth factor and human insulin have been put into the market, and nearly one third of them are countries. Innovative drugs. There are more than 10 varieties in clinical research. Although many projects are still in the research stage, the rapid development of bioengineering technology has become a flashing highlight in the pharmaceutical market, and will surely become the fastest growing segment of the pharmaceutical industry.
  Power comes from the market
  In recent years, with the impact of ecological environment, increased living pressure and age, the prevalence of malignant tumors is gradually increasing, and the spread of immunodeficiency virus and hepatitis B and hepatitis C virus diseases has jointly promoted the market of genetic technology drugs. And it shows rapid development.
However, on the other hand, the development of China's biopharmaceutical industry is not smooth. After the rapid growth period in the mid-to-late 1990s, in the tide of the world tide, and the low-key operation of the domestic stock market, the creatures The pharmaceutical industry has also experienced a period of low tide. In 2002, listed companies with biopharmaceuticals as their main business also showed poor performance and slowed development due to leading product factors.
  The development of the market also has its special trajectory, which is not transferred by the will of the people. Affected by the sudden impact of SARS virus, biopharmaceuticals such as interferon and thymosin have become the best prescriptions for controlling atypical pneumonia. The biopharmaceutical sector has once again received widespread attention, promoting the development of the biomedical market and small and medium-sized high-tech enterprises such as Beijing. The successful listing of Shuanglu Pharmaceutical. Looking into the future, the bio-pharmaceutical industry will take this opportunity to open up new bio-pharmaceutical markets with new product development to drive breakthroughs in technical barriers, and will enable China's bio-engineering and pharmaceutical industries to join hands in a higher development platform.
  In recent years, China's pharmaceutical industry has continued to grow at a high speed. In 2003, the sales revenue of the national pharmaceutical industry products reached 296.2 billion yuan, an increase of 19% over the previous year, and realized a profit of 27.4 billion yuan, an increase of 25.8% over the previous year. Pharmaceutical restructuring and mergers and acquisitions are in full swing: the eight major medical systems, such as Huayuan, Fosun, Taiji, Taitai, Dongsheng, Yuanda, Huali, and China Resources, which are most active in the capital field, have surfaced. “Pharmaceutical Valley” heat has attracted huge investment: At present, there are more than 100 pharmaceutical industry parks in the country, and there are more than 50 biomedical parks approved by relevant state departments or local governments.
  From the perspective of Beijing's bioengineering and pharmaceutical industry, the current value of production in 2003 has reached 15 billion yuan, and the total profit accounted for 14.57%. From the structural analysis, the ratio of chemical pharmaceutical, bioengineering and natural medicine is 50:17:33, bioengineering pharmaceutical industry. The total output value is 1.67 billion yuan. In the next step, the government will encourage industrial research on bioinformatics, biochip technology, gene therapy technology, and cell therapy technology, and encourage the development of biodiagnostic chips, cellular immunotherapy drugs, monoclonal antibody diagnostic reagents, and genetic engineering drugs. And vaccines and other products.
  Looking back on the development of biotechnology drugs, after more than 30 years of embarrassment, it has already begun to take shape. In the pharmaceutical market, biotech drugs have become an important and important category for cancer, human immunodeficiency virus disease, cardiovascular disease, diabetes, anemia, autoimmune diseases, genetic defects and many genetic diseases. The development of bioengineering technology is changing rapidly, which promotes the research process of recombinant DNA technology, molecular cloning technology and cell fusion technology.
  The bio-genetic engineering industry faces the situation of economic globalization. There are opportunities for development at any time. In the process of bio-genetic engineering research, scale-up production and market development, China has very much in terms of management system, capital, technology and talents. The big gap, while also weak in patent protection and patent research, is a well-known fatal "soft rib." Only by accelerating the adjustment of industrial structure, improving quality and efficiency, and rationally arranging limited resources to form a scientific and rational R&D and production pattern will be beneficial to the development of new bio-industries.